EUVIMEDEUVIMED entdecken
Open Access

ACKR3 upregulation under hyperglycemia associates with endothelial dysfunction

Seyedeh Zohreh Azarshin iD, Zahra Abedi Kichi, Shahram Rabbani, Mohammad Ali Boroumand, Mousa Golalizadeh Lahi, Mehrdad Behmanesh iD

Advanced Pharmaceutical Bulletin · 10.05.2026

DOI: 10.34172/apb.46517 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Pharmaceutical Bulletin, online erschienen am 10.05.2026. Verfasst von Seyedeh Zohreh Azarshin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Diabetes is a metabolic disorder characterized by chronic hyperglycemia and is associated with cardiovascular complications. Endothelial cell dysfunction is a common feature of both diabetes and its vascular complications. In this study, RNA-seq data from aortic specimens of diabetic patients were analyzed to identify candidate genes that are potentially involved in regulating endothelial cell function under hyperglycemic conditions. Among the identified GPCRs, ACKR3 was singled out as a promising candidate.

Methods

Expression of ACKR3 in the vessels of diabetic animals and the HUVEC cell line under hyperglycemia conditions was assessed. Subsequently, the function of the ACKR3 gene was investigated by downregulation of ACKR3 at hyperglycemic conditions in the HUVEC cell line.

Results

Our data showed that expression of Ackr3 in the vessels of diabetic animals was increased. Furthermore, treatment of HUVECs under hyperglycemic conditions (25 mM D-glucose) for 24 h and 48 h resulted in elevated ACKR3 expression at both mRNA and protein levels. Functional analyses revealed that ACKR3 downregulation resulted in significant reductions in oxidative stress levels, inflammation, and the rate of endothelial cell apoptosis under hyperglycemic conditions. Additionally, ACKR3 downregulation reduced the expression of adhesion molecules (ICAM and VCAM), leading to decreased monocyte adhesion under hyperglycemic conditions.

Conclusion

Our findings suggest that hyperglycemia-induced ACKR3 up-regulation may contribute to endothelial cell dysfunction in diabetic vessels. Therefore, targeting ACKR3 could offer valuable insights for developing therapeutic strategies against diabetes-related vascular complications.

Schlagwörter

Stichwörter der Autor:innen

ACKR3Diabetes mellitusEndothelial cellGPCRsHyperglycemia

Autor:innen und Institutionen

  • Department of Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran.
  • Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians University Munich, 80336 Munich, Germany.
  • Research Center for Advanced Technologies in Cardiovascular Medicine, Tehran University of Medical Sciences, Tehran, Iran.
  • Cardiovascular Diseases Research Institute, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Department of Statistics, Faculty of Mathematical Sciences, Tarbiat Modarres University, Tehran, Iran.

ORCID-Profile: Seyedeh Zohreh Azarshin, Mehrdad Behmanesh

Zitieren

APA

Azarshin, S. Z., Abedi Kichi, Z., Rabbani, S., Boroumand, M. A., Golalizadeh Lahi, M., & Behmanesh, M. (2026). ACKR3 upregulation under hyperglycemia associates with endothelial dysfunction. Advanced Pharmaceutical Bulletin. https://doi.org/10.34172/apb.46517

Vancouver

Azarshin SZ, Abedi Kichi Z, Rabbani S, Boroumand MA, Golalizadeh Lahi M, Behmanesh M. ACKR3 upregulation under hyperglycemia associates with endothelial dysfunction. Advanced Pharmaceutical Bulletin. 2026. doi:10.34172/apb.46517

BibTeX
@article{Azarshin2026,
  author = {Azarshin, Seyedeh Zohreh and Abedi Kichi, Zahra and Rabbani, Shahram and Boroumand, Mohammad Ali and Golalizadeh Lahi, Mousa and Behmanesh, Mehrdad},
  title = {ACKR3 upregulation under hyperglycemia associates with endothelial dysfunction},
  journal = {Advanced Pharmaceutical Bulletin},
  year = {2026},
  doi = {10.34172/apb.46517}
}
Kostenlos starten →